VEGF is a mediator in the pathogenesis of certain eye conditions, including wet age-related macular degeneration (AMD), diabetic retinopathy and macular oedema secondary to retinal vein occlusions.

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Diabetic macular edema can result in low vision or ... When fluid gets into the retina’s center part, called the macula, it causes swelling. This can affect vision and, in some cases, lead ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...